从资金流向上来看，当日动物保健板块主力资金净流入1802.32万元，游资资金净流出2735.26万元，散户 资金净流入932.94万元。动物保健板块个股资金流向见下表： 证券之星消息，1月28日动物保健板块较上一交易日下跌0.2%，永顺生物领跌。当日上证指数报收于 4151.24，上涨0.27%。深证成指报收于14342.9，上涨0.09%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 18.78 | 1.51% | 71.49万 | | 13.16亿 | | 002688 | 金河生物 | 6.80 | 1.49% | 37.94万 | | 2.55 Z | | 920970 | 大禹生物 | 8.35 | 1.46% | 4.01万 | | 3369.19万 | | 002868 | *ST绿康 | 35.41 | 0.03% | 2.68万 | | 9485.97万 | | 600195 | 中牧股份 | 8. ...

每经讯，2026年1月27日，北交所上市公司永顺生物（920729，收盘价：10.95元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日换手率达到30.52%，成交数量2344.63万股，成交金额2.45亿元。买一席位为东方财富证券股份有限公司拉萨东环路第二 证券营业部，买入739.89万元；卖一席位为光大证券股份有限公司北京总部基地营业部，卖出610.51万元。 （记者 曾健辉） | | 2026-01-27永顺生物 (920729) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | ਜੇਟ ਹ | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 7398892.82 | 2833297.74 | | 买2 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | 5315437.55 | 2509545.89 | | 址3 | 国信证券股份有限公司深圳互联网分公司 | 4244010.63 | 2950816.6 | | 买4 | 中国银河证券股份有限公司北京远大路证券营业部 | 4208473.1 ...

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5952.91万元，其中，买入成交额为 2524.84万元，卖出成交额为3428.07万元，合计净卖出903.23万元。 永顺生物（920729）今日下跌7.12%，全天换手率30.52%，成交额2.45亿元，振幅10.48%。龙虎榜数据 显示，营业部席位合计净卖出903.23万元。 北交所公开信息显示，当日该股因日换手率达30.52%上榜，营业部席位合计净卖出903.23万元。 具体来看，今日上榜营业部中，第一大买入营业部为东方财富证券股份有限公司拉萨东环路第二证券营 业部，买入金额为739.89万元，第一大卖出营业部为光大证券股份有限公司北京总部基地营业部，卖出 金额为610.51万元。（数据宝） 永顺生物1月27日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 东方财富证券股份有限公司拉萨东环路第二证券营业 | 739.89 | 283.33 | | | 部 | | | | 买二 | 东方财富证券股份有限公司拉萨团结路第二证券营业 | ...

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Group 1 - The core point of the news is that Yongshun Biological (920729) has seen a net financing inflow of 25.57 million yuan on October 29, 2025, with a total financing balance of 1,300.67 million yuan, indicating a positive trend in investor interest [1][2][3] - Over the past three trading days, the cumulative net buying has reached 57.1 million yuan, reflecting a consistent increase in financing activity [1] - The financing balance increased by 2.01% compared to the previous day, showing a growing confidence among investors [2][3] Group 2 - The financing net buying on October 28 was 11,700 yuan, and on October 27, it was 303,600 yuan, indicating fluctuations in investor activity [2] - The financing balance on October 24 was 1,243.57 million yuan, which decreased by 21,170 yuan, highlighting a brief period of reduced investor engagement [2][3] - The overall margin trading balance on October 29 was 1,300.67 million yuan, marking a significant increase in trading activity [3]

Core Viewpoint - Yongshun Biological has demonstrated strong operational resilience with a slight increase in net profit despite a decrease in revenue, indicating effective cost control and product optimization strategies [1][2]. Financial Performance - In the first three quarters of 2025, Yongshun Biological achieved operating revenue of 180 million yuan, with a net profit attributable to shareholders of 30.28 million yuan, reflecting a year-on-year growth of 4.56% [1]. - The company's operating income decreased by 10.18% year-on-year, attributed to the cyclical fluctuations in the pig farming industry [2]. - The net cash flow from operating activities reached 74.66 million yuan, a significant increase of 34.97% year-on-year, indicating strong cash flow management [2]. - Asset impairment losses were reduced by 75.49% year-on-year, primarily due to improved inventory turnover and efficiency [2]. Product Development and Innovation - Yongshun Biological has focused on innovation, investing 15.31 million yuan in R&D, which is approximately 8.50% of its operating revenue [3]. - The company has recently obtained production licenses for two significant products: a quadrivalent inactivated vaccine for avian influenza and a bivalent inactivated vaccine for H5 subtype avian influenza, enhancing its market position in poultry vaccines [3]. - Additional product approvals include a new vaccine for pigeon newcastle disease and several other vaccines for swine diseases, indicating a robust pipeline for future growth [3]. Industry Outlook - The pig farming industry is expected to rebound in the fourth quarter, supported by policy adjustments and market corrections, positioning Yongshun Biological favorably for sustained growth in the upcoming industry cycle [4].

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]